

## DAFTAR PUSTAKA

- Abenovali, L., Corpechot, C., Poupon, R., 2007. Elastography In Hepatology. *Can J gastroenterology*. 21(12):839-842
- Abraldes, J.G., Villanueva, C., Aracil, C., Turnes, J., Hernandez-Guerra, M., Genesca, J., *et al.* 2016. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. *Gastroenterolo*. 150:1160–1170.
- Abraldes, J.G., Albillos, A., Bañares, R., Turnes, J., González, R., García-Pagán, JC., & Bosch, J. 2009. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. *Gastroenterol*, 136(5):1651-8.
- Adinolfi, L. E., Giordano, M. G., Andreana, A., Tripodi, M.F., Utili, R., Cesaro, G., 2001. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. *British Journal of Haematology*. 113(3):590-5.
- Afdhal, N., McHutchison, J., Brown, R., Jacobson, I., Manns, M., Poordad, F., *et al.* 2008. Thrombocytopenia associated with chronic liver diseases. *J of Hepatol*. 48:1000-1007.
- Ajayi, O. i., akindo, D.B., Okafar, A.M., 2016. Correlation between Body Mass Index and hematological indeces in young adult Nigeria with different hemoglobin genotype. *American journey of biomedical science*. 9(1):38-46.
- Akçiçek, F., Ok, E., Duman, S., Kürsad, S., Unsal, A., Alev, M., *et al.* 1996. Lipid-lowering effects of simvastatin and gemfibrozil in CAPD patients: a prospective cross-over study. *Adv Perit Dial.*, 12, 261-5.
- Bataller, R., Brenner, D., 2005. Liver Fibrosis. *The Journal of Clinical Investigation*. 115 (2):209-18.
- Bays, H., Cohen, D.E., Chalasani, N., Harrison, SA. 2014. An assessment by the Statin Liver Safety Task Force: 2014 update. *J Clin Lipid*. 8:S47–S57.
- Benter, T., Kluhs, L., Teichgraber, U., 2011. Sonography of the spleen. *J Ultrasound Med*. 30:1281-1293.
- Bougie, W. D., Wilher, R. P., Asper, R. H., 2006. Patient with Quinine-induced imune thrombocytopenia have both drug dependent and drug specific antibodies. *The American Society oh Hematology*. 108(3):927-977
- Canbay, A., Friedman, S., Gores, G.J. 2002. Apoptosis: the nexus of liver injury and fibrosis. *Hepatology*. 39:273-278.
- Cherian, J.V., Deepak, N., Ponnusamy, R.P., Somasundaram, A., Jayanthi, V., 2011. Non-invasive predictors of esophageal varices. *Saudi J Gastroenterol*. 7(1):64-8.
- Cobbold, J.F.L., Morin, S., Taylor-Robinson, S.D., 2007. Transient Elastography For The Assesment Of Chronic Liver Disease: Ready For Clinic?. *World J Gastroenterology*. 13(36):4791-4797
- Cohen-Naftaly, M., Friedman, S.L., 2011. Current status of novel antifibrotic therapies in patients with chronic liver disease. *Ther Adv Gastroenterol*. 4(6):391-417.

- Colderon, R.M., Cubeddu, L.V., Golberg, R.B., Schiff, E.R., 2010. Statin in the treatment of elevated liver aminotransferase levels: a therapeutic dilemma. *Mayo Foundation for Medical Education and Research*. 85(4): 349-56
- Dahlan, M.S., 2009. Besar sampel dan cara pengambilan sampel dalam penelitian kedokteran dan kesehatan. *Salemba Medika*. Jakarta.
- Dale, K.M., White, C.M., Henyan, N.N., 2007. Impact of statin dosing intensity on transaminase and creatinin kinase. In: database of abstract og review of effects (DARE).
- D'Amico, G., Garcia-Tsao, G., Pagliaro, L., 2006. Natural history and prognostic indicators of survival in cirrhosis: A systematic review of 118 studies. *Journal of Hepatology*. 44 (10): 217-31
- Dancygier, H., 2010. Clinical scoring systems. In: H. Dancygier (ed.) *Clinical Hepatology*. Verlag Berlin Heidelberg: springer, 289-290.
- Fadhilah, A.H., Yaswir, R., Syah, N.A., 2017. Gambaran jumlah trombosit berdasarkan berat ringannya penyakit pada pasien sirosis hati dengan perdarahan di RSUP Dr. M Djamil Padang. *Jurnal kesehatan andalas*. 6(3):609-614
- Franchis, R., 2005. Report Of The Baveno IV Consensus Workshop on Methodology Of diagnosis and Therapy In Portal Hypertension. *Evolving concensus In Portal Hypertension*. 43: 167-176
- Friedman, S.L., 2008. Mechanisms of hepatic fibrogenesis. *Gastroenterology*. 134:1655-1669.
- Friedmann, S., 2003. Liver Fibrosis-from bench to bedside. *Journal Of Hepatology*. 38:38-53.
- Garcia-Tsao, G., Lim, J., Monto, A., Yee, H., Durfee, J., Dieperink E., 2009. Management and Treatment of Patients With Cirrhosis and Portal Hypertension: Recommendations From the Department of Veterans Affairs Hepatitis C Resource Center Program and the National Hepatitis C Program. *Am J Gastroenterol*. 104:1802-1829.
- Gigante, A., Giralidi, G.D.L., Amoroso, D., Barbano, B., Doreli, B., Mario, F.D., 2013. Statin in chronic liver disease. *AME Med J*. 2018 2(2).
- Goodman, L.S., Gilman, A., 2008. The Pharmacological Basis Of Therapeutics. 11th ed. McGraw-Hill Companies, United State Of America.
- Goulis, J., Chau, T.N., Jordan, S., Mehta, A.B., Watkinson, A., Rolles, K., 1999. Thrombopoietin concentrations are low in patients with cirrhosis and thrombocytopenia and are restored after orthotopic liver transplantation. *Gut*. 44:754-758.
- Guyton, A.C., Hall. 2011. *Buku Ajar Fisiologi Kedokteran*, ed 12, Penerbit Buku Kedokteran EGC, Jakarta
- Hadi, Sujono., 2012. *Gastroenterologi*. Bandung. PT. Alumni. 402-403, 613-647 1643-1646.
- Hoffbrand, A.V., Petit, J.R., Moss, P.A.H., 2005. *Kapita Selektta Hematologi*, p221-295. Edisi 4: Penerbit Buku Kedokteran EGC, Jakarta.
- Imamura, M., Ogawa, T., Sasaguri, Y., Chayama, K., Ueno, H., 2005. Suppression of macrophage infiltration inhibits activation of hepatic stellate cells and liver fibrogenesis in rats. *Gastroenterology*. 128: 138-46.

- Ito, D., Ito, O., Mori, N., Muroya, Y., Cao, P.Y., Takashima, K., *et al.* 2010. Atorvastatin upregulates nitric oxide synthases with Rho-kinase inhibition and Akt activation in the kidney of spontaneously hypertensive rats. *Journal Hypertensi.* 28(11):2278-88.
- Jain, M., Verges, J., Venkatratraman, J., 2017. Antiviral induced thrombocytopenia. *World Journal of pharmacology.* 6(2): 11-13
- Janicko, M., Drazilova S., Pella, D., Fedacko, J., Jarcuska, P., 2016. Pleiotropic effect of statins in the disease of the liver. *World J Gastroenterol.* 22(27): 209 - 15
- Jones, S.P., Gibson, M.F., Rimmer, D.M., Gibson, T.M., Sharp, B.R., Lefer, D.J. 2002. Direct vascular and cardioprotective effects of rosuvastatin, a new HMG-COA reductase inhibitor. *J Am Coll Cardiol.* 40:1172-8.
- Jones, P.H., Davidson, M.H., Stein, E.A., Bays, H.E., McKenney, J.M., Miller, E., *et al.* 2003. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR Trial). *The American Journal of Cardiology.* 93:152-160.
- Kajihara, M., Kato, S., Okazaki, Y., Kawakami, Y., Ishii, H., Ikeda, Y., 2003. A role of autoantibody-mediated platelet destruction in thrombocytopenia in patients with cirrhosis. *Hepatologi.* 37:1267-1276.
- Katzung, B.G., 2002. Farmakologi Dasar dan Klinik, edisi II. Jakarta, *Salemba Medika.* 671-678.
- Kawasaki, T., Takeshita, A., Souda, K., Kobayashi, Y., Kikuyama, M., Suzuki, F., *et al.* 1999. Serum thrombopoietin levels in patients with chronic hepatitis and liver cirrhosis. *Am J Gastroenterol.* 94(7):1918-1922.
- Knoop, R., 1999. Drug treatment of lipid disorders. *N Engl J Of Med.* 341(7):498-511.
- Kumar, S., Grace, N.D., Qamar, A.A., 2014. Statin Use in Patients with Cirrhosis: A Retrospective Cohort Study. *Dig Dis Sci.* 59:1958-1965.
- Kusumobroto, H.O., 2007. Sirosis Hati. In: Sulaiman, A., Akbar, H.N., Nurul, A. Lesmana, L.A., Noer, M.S. (Ed.) *Buku Ajar Ilmu Penyakit Hati*, p335-45. Jaya Abadi, Jakarta.
- Laufs, U., Endres, M., Stagliano, N. Amin-Harjani, S., Chui, D.S., Yang, S.X., 2000a. Neuroprotection mediated by changes in the endothelial actin cytoskeleton. *J. Clin. Invest.* 106:15-24.
- Laufs, U., Gertz, K., Huang, P., Nickenig, G., Bohm, M., Dirnagl, U., Endres, M. 2000b. Atorvastatin Upregulates Type III Nitric Oxide Synthase in Thrombocytes, Decreases Platelet Activation, and Protects From Cerebral Ischemia in Normocholesterolemic Mice. *Stroke AHA Journals.* 31:2437-49.
- Liao, J.K., 2002. Isoprenoids as mediators of the biological effects of statins. *J Clin Invest.* 110:285-288.
- Lisman, T., Leebeek, F.W.G., 2007. Hemostatic Alterations in Liver Disease: A Review on Pathophysiology, Clinical Consequences, and Treatment. *Digestive Surgery.* 24:250-258.
- Loo, M., Beguin, Y., 1999. The effect of recombinant human erythropoietin on platelet counts is strongly modulated by the adequacy of iron supply. *Blood.* 93(10):3286-3293.
- Mason, J.C., 2003. Statins and their role in vascular protection. *Clinical Science.* 105:251-266.

- Mason, R.P., Corbalan, J.J., Jacob, R.F., Dawoud, H., Malinski, T., 2015. Atorvastatin enhanced nitric oxide release and reduced blood pressure, nitroxidative stress and rantes levels in hypertensive rats with diabetes. *Journal Of Physiology And Pharmacology*. 66(1):65-72.
- McGirt, M.J., Lynch, JR., Parra, A., Sheng, H., Pearlstein, R.D., Laskowitz, D.T., *et al.* 2002. Simvastatin increases endothelial nitric oxide synthase and ameliorates cerebral vasospasm resulting from subarachnoid hemorrhage. *Stroke*. 33:2950-2956.
- Mitchell, O., Feldman, M.D., Diakow, M., Siagal, H.S., 2016. The Pathophysiologi of thrombocytopenia in chronic liver disease. *Hepatic Medicine*. 8:39-50.
- Mulyadi, B., Soemarsono, J., Trombositopenia pada pengobatan heparin. 2007. *Indonesian Journal of Clinical Pathology and Medical Laboratory*. 13:113-117.
- Nangle, M.R., Cotter, M.A., Cameron, N.E., 2003. Effects of rosuvastatin on nitric oxide-dependent function in aorta and corpus cavernosum of diabetic mice : relationship to cholesterol biosynthesis pathway inhibition and lipid lowering. *Diabetes*. 52:2396-2402.
- Nurdjanah, S., 2009. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*, P668-73. Edisi V Jilid I. Interna Publishing, Jakarta.
- Nurdjanah S. 2014. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*, p1978-83. Edisi VI Jilid II: *Interna Publishing*, Jakarta
- Park, J.G., Tak, W.Y., Park, S.Y., Kweon, Y.O., jang, S.Y., Lee, Y.R., *et al.*, 2017. Effect of Branched-Chain Amino Acids (BCAAs) on the progression of advanced liver disease. *Medicine*. 96:24
- Price, S. And Wilson, L., 1994. *Patofisiologi Konsep Klinis Proses-Proses Penyakit*. Jakarta. EGC
- Prihartini, J., Lesmana, L.A., Manan, C., Gani, R.A., 2005. Detection of Esophageal Varices In Liver Cirrhosis Using Non-invasive Parameters. *The Indonesian Journal of Internal Medicine, Acta Medica Indonesiana*. 37(3):126-31.
- Pugh, R.N., Murray-Lyon, I.M., Dawson, J.L., Pietroni, M.C., Williams, R., 1973. Transection of the oesophagus for bleeding oesophageal varices. *The British journal of surgery*. 60(8):646-9.
- Putut, B. 2014. Sirosis Hati. In: A. W. Sudoyo, B. Setiyohadi, I. Alwi, *et al.* (eds) *Buku Ajar Ilmu Penyakit Dalam*, p2009-14. Edisi VI Jilid II: *Interna Publishing*, Jakarta
- Rockey, D.C. and Friedman S.C., 2008. Hepatic Fibrosis and Cirrhosis in Zakim and Boyer's Hepatology (Fifth Edition). *Elsevier*: 87-103.
- Rodriguez-Yanez, M., Davalos, A., Castilo, J., 2008. Withdrawal from statin: Implication for secondary stroke prevention and acute treatment. *Sage journal*. (3): 85-87
- Rossoni, L.V., Wareing, M., Wenceslau, C.F., Al-Abri, M., Cobb, C., Austin, C., 2011. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. *Clinical Science*. 121:449-458.

- Russo, W.M. and Jacobson, M., 2004. How to use statin in patients with chronic liver disease. *Cleveland Clin J of Med*. 71:58-62.
- Sadowitz, B., Maier, K.G., Gahtan, V., 2010. Basic science review : Therapy-part I: the pleiotropic effects of statin in cardiovascular. *Vascular and endocardiovascular surgery*. 44(4):241-51.
- Sarangapani, A., Shanmugam, C., Kalyanasundaram, M., Rangachari, B., Thangavelu P., Subbarayan, J.K., 2010. Noninvasive prediction of large esophageal varices in chronic liver disease patients. *Saudi J Gastroenterol*. 16(1):38-42.
- Sherlock, S., Dooley, J.D., 2002. Hepatic Cirrhosis. In: S. Sherlock and J. D. Dooley (eds.) *Diseases of the Liver and Biliary System* Eleventh ed.: Blackwell Science.
- Shirin, H., Sharvit, E., Aeed, H., Gavish, D., Bruck, R., 2013. Atorvastatin and rosuvastatin do not prevent thioacetamide induced liver cirrhosis in rats. *World J Gastroenterol*. 9(2):241:48.
- Stancu, C., Sina, A., 2001. Cirrhosis: diagnosis, management, and prevention. *Am Fam Physc*. 84(12):1353-59.
- Tandon, V., Bano, G., Khajuria, V., Parihar, A., Gupta S., 2004. Pleiotropic effect of statins. *Indian J Pharmacol*. 37(2):77-85.
- Temel, T., Cansu, D.U., Temel, H.E., Ozakyo, A.H., 2014. Serum Thrombopoietin Levels and Its Relationship With Thrombocytopenia in Patients With Cirrhosis. *Hepat Mon*. 14(5):e18556.
- Trocha, M., Merwid-L, A., Szuba, A., Chlebda, E., Pieoeniewska, M., Sozański, T., et al. 2010. Effect of simvastatin on nitric oxide synthases (eNOS, iNOS) and arginine and its derivatives (ADMA, SDMA) in ischemia/reperfusion injury in rat liver. *Pharmacological Reports*. 62:343-351.
- Tsochatzis, E.A., Bosch, J., Burroughs, A.K., 2014. Liver cirrhosis. *Royal Free Sheila Sherlock Liver Centre*. S0140-6736(14):60121-5.
- Wang, C.S., Yao, W.J., Wang, S.T., Chang, T.T., Chou, P., 2004. Strong association of hepatitis C virus (HCV) infection and thrombocytopenia: implications from a survey of a community with hyperendemic HCV infection. *Clin Infect Dis*. 39(6):790-796.
- Witztum, J.L., 1996. Drugs Used in the Treatment of Hyperlipoproteinemias. In: Molinoff, P.B., and Ruddon, R.W. (editor). *Goodman & Gilman's The Pharmacological Basic Of Therapeutics*. Edisi 9. New York : McGraw Hill, Inc., 887.
- Wu, H.S., 2008. Image segmentation of liver fibrosis. *Journal of Microscopy*. 231:70-80
- Yoshiji, H., Kuriyama, S., Miyamoto, Y., Thorgeirsson, U.P., Gomez, D.E., Kawata, M. et al., 2012. Tissue inhibitor of metalloproteinases-1 promotes liver fibrosis development in a transgenic mouse model. *Hepatology*. 32:1248-1254.
- Zafra, C., Abraldes, J.G., Turnes, J., Berzigotti, A., Fernández, M., Garca-Pagán, J.C., et al. 2004. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. *Gastroenterology*. 126(3):749-55.